dabrafenib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

JS InnoPharm, LLC (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadmeasurable disease

I am/have/hadcancer

I am/have/hadneutrophil count

I am/have/hadmetastasis

I am/have/hadmetastatic melanoma

I am/have/hadgilbert's syndrome

I am/have/hadserum pregnancy test

I am/have/hadsolid neoplasm

I am/have/hadlung cancer

I am/have/hadbrain metastasis

I am/have/hadliver metastasis

I am/have/hadmetastatic malignant solid neoplasm

I am/have/hadalt/ast

I am/have/hadnon-small cell lung cancer

I am/have/hadadjuvant therapy

I am/have/hadsmall cell lung cancer

I am/have/hadbrain metastases

I am/have/hadstage iv nsclc

I am/have/hadgene fusion

I am/have/hadexperimental therapy

added new label for I am/have/had

more

I am looking for

I am looking fordabrafenib

I am looking formelanoma

I am looking formek inhibitor

I am looking foradjuvant

I am looking foripilimumab

I am looking forras-gap

I am looking forras-gef

I am looking forimmunomodulator

I am looking forimmunomodulators

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Recruiting

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

non-small cell lung cancer

metastatic melanoma

ras-gap

neutrophil count

investigational treatment

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.